Search

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Sustainable Development - Our Commitment

Our Commitment

More Green | Sustainable Development

Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.

Ordering your medicine online? Find a safe pharmacy first.

Learn what to look for when buying medication and how to verify your pharmacy.

Our Innovation Prize | Partnering

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.

Fostering Science | Boehringer Ingelheim US

Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.

The Importance of Drug Discovery | R&D | Boehringer Ingelheim US

Research & Development

BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US

BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Technologies

We are expanding our global network of technology partners. Learn more about partnering with us.

Partnering Culture

BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.

Parasiticides

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Our Culture of Caring: Volunteering

At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.

FDA approved treatment option for adults with CKD

The FDA has approved Jardiance® (empagliflozin) tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression.

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.

Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US

Find out more on how Boehringer Ingelheim are going carbon neutral at our manufacturing plant in Gainesville, Georgia, embracing sustainability.

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Boehringer Cares Patient Assistance Portal

Click here to find out more about Boehringer Ingelheim's Boehringer Cares patient assistance program portal.

A Planned Safety Net for Patients in Need

Innovation in CardioMetabolic Disease Research

Expanded Access Programs

FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US

FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.

Protein Degraders: Changing the Game in Cancer Drug Discovery

Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers